Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: cyclophosphamideBiological: rituximabDrug: doxorubicinDrug: prednisoneDrug: vincristineRadiation: tositumomab
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 571
- Registration Number
- NCT00006721
- Locations
- 🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: sargramostimDrug: busulfanProcedure: Allogeneic HCTDrug: cyclophosphamideDrug: cytarabineDrug: gemtuzumab ozogamicin (GO)Drug: DaunorubicinProcedure: Autologous HCT
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 657
- Registration Number
- NCT00049517
- Locations
- 🇺🇸
Community Medical Center, Missoula, Montana, United States
🇺🇸Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
- Conditions
- LeukemiaLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Biological: anti-thymocyte globulinBiological: filgrastimDrug: cyclophosphamideDrug: cytarabineDrug: methylprednisoloneDrug: thiotepaProcedure: in vitro-treated bone marrow transplantationProcedure: in vitro-treated peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00002718
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- EBMT Solid Tumors Working Party
- Target Recruit Count
- 460
- Registration Number
- NCT00005589
- Locations
- 🇩🇪
Universitaetsklinikum Goettingen, Goettingen, Germany
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1076
- Registration Number
- NCT00005596
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 838
- Registration Number
- NCT00005585
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
- Conditions
- Unspecified Childhood Solid Tumor, Protocol SpecificChronic Myeloproliferative DisordersLeukemiaMyelodysplastic SyndromesNonmalignant NeoplasmUnspecified Adult Solid Tumor, Protocol SpecificLymphomaMyelodysplastic/Myeloproliferative Diseases
- Interventions
- Biological: anti-thymocyte globulinDrug: busulfanDrug: fludarabine phosphateDrug: carboplatinRadiation: total-body irradiationDrug: cyclophosphamideDrug: melphalanDrug: etoposideDrug: thiotepa
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 361
- Registration Number
- NCT00003816
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
- Conditions
- Brain TumorsCentral Nervous System TumorsMedulloblastoma
- Interventions
- Drug: CisplatinDrug: CyclophosphamideDrug: EtoposideDrug: LomustineDrug: VincristineRadiation: Craniospinal Radiation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 30
- Registration Number
- NCT00031590
- Locations
- 🇺🇸
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Surgery in Treating Children With Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- Procedure: conventional surgeryBiological: filgrastimRadiation: radiation therapyBiological: sargramostimDrug: carboplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideProcedure: adjuvant therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 968
- Registration Number
- NCT00003119
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Illinois Medical Center, Chicago, Illinois, United States
Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
- Conditions
- Kidney Cancer
- Interventions
- Biological: dactinomycinDrug: vincristine sulfateBiological: filgrastimDrug: doxorubicin hydrochlorideProcedure: conventional surgeryDrug: cyclophosphamideRadiation: radiation therapyDrug: etoposide
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3031
- Registration Number
- NCT00002611
- Locations
- 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.